Effect of fish oil supplementation on hyperlipidemia during childhood acute lymphoblastic leukemia treatment - A pilot study
Research output: Contribution to journal › Journal article › Research › peer-review
Standard
Effect of fish oil supplementation on hyperlipidemia during childhood acute lymphoblastic leukemia treatment - A pilot study. / Laumann, Renate D; Iversen, Turid; Mogensen, Pernille R; Lauritzen, Lotte; Mølgaard, Christian; Frandsen, Thomas Leth.
In: Nutrition and Cancer, Vol. 73, No. 9, 2021, p. 1816-1820.Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Effect of fish oil supplementation on hyperlipidemia during childhood acute lymphoblastic leukemia treatment - A pilot study
AU - Laumann, Renate D
AU - Iversen, Turid
AU - Mogensen, Pernille R
AU - Lauritzen, Lotte
AU - Mølgaard, Christian
AU - Frandsen, Thomas Leth
N1 - CURIS 2021 NEXS 264
PY - 2021
Y1 - 2021
N2 - Hyperlipidemia is common during contemporary treatment of childhood acute lymphoblastic leukemia and may increase risk of osteonecrosis, thrombosis, and possibly acute pancreatitis. Marine fatty acids found in fish oil decrease levels of triglycerides and possibly total cholesterol in hyperlipidemic patients. This prospective pilot study provided fish oil for 83 days to seven children undergoing acute lymphoblastic leukemia treatment. On average fish oil was consumed 74% of the intervention period. Further, we found significant lower levels of triglycerides (P = 0.016) and total cholesterol (P = 0.027) compared to 22 historical controls, although correction for one extra PEG-asparaginase dose reduced the level of significance. However, the findings indicate that fish oil may alleviate development of hyperlipidemia during acute lymphoblastic leukemia treatment. Randomized controlled trials are warranted to confirm these findings and to investigate the potential effect of fish oil supplements on development of severe adverse events, including osteonecrosis, thrombosis, and acute pancreatitis.
AB - Hyperlipidemia is common during contemporary treatment of childhood acute lymphoblastic leukemia and may increase risk of osteonecrosis, thrombosis, and possibly acute pancreatitis. Marine fatty acids found in fish oil decrease levels of triglycerides and possibly total cholesterol in hyperlipidemic patients. This prospective pilot study provided fish oil for 83 days to seven children undergoing acute lymphoblastic leukemia treatment. On average fish oil was consumed 74% of the intervention period. Further, we found significant lower levels of triglycerides (P = 0.016) and total cholesterol (P = 0.027) compared to 22 historical controls, although correction for one extra PEG-asparaginase dose reduced the level of significance. However, the findings indicate that fish oil may alleviate development of hyperlipidemia during acute lymphoblastic leukemia treatment. Randomized controlled trials are warranted to confirm these findings and to investigate the potential effect of fish oil supplements on development of severe adverse events, including osteonecrosis, thrombosis, and acute pancreatitis.
KW - Faculty of Science
KW - Acute lymphoblastic leukaemia (ALL)
KW - Docosahexaenoic acid (DHA)
KW - Eicosapentaenoic acid (EPA)
KW - Fish oil (FO)
KW - Total cholesterol (TC)
KW - Triglyceride (TG)
U2 - 10.1080/01635581.2020.1803934
DO - 10.1080/01635581.2020.1803934
M3 - Journal article
C2 - 32791015
VL - 73
SP - 1816
EP - 1820
JO - Nutrition and Cancer
JF - Nutrition and Cancer
SN - 0163-5581
IS - 9
ER -
ID: 247034071